STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more

Eli Lilly's obesity drug retatrutide showed significant weight loss in a Phase 3 study but did not reduce cardiovascular risk. The U.S. Medicare program is offering injectable GLP-1 obesity medications like Wegovy, Foundayo, and Zepbound through a trial program for $50 monthly, with high patient demand for injectables despite expectations of pill preference.